Ergoteles’s Minerva Neurosciences NERV Stock Holding History

Ergoteles’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-20,263	Closed	-$376K	–	1530
2021 Q2	$376K	Buy	+20,263	New	+$436K	0.01%	951

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's NERV Position: Q3 2021 in Review

Ergoteles sold out of Minerva Neurosciences (NERV) in Q3 2021, closing a stake of 20,263 shares — an estimated $376K sold.

Ergoteles first reported a position in NERV in Q2 2021 and held it in 1 quarter. The position peaked at $376K in Q2 2021. 46 funds tracked by Wall St. Rank hold NERV as of Q3 2021.

Ergoteles reported no remaining Minerva Neurosciences position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 20,263 Minerva Neurosciences shares in Q3 2021, an estimated $376K.
Ergoteles first reported a position in Minerva Neurosciences in Q2 2021 and held it in 1 quarter.
Ergoteles's Minerva Neurosciences position peaked at $376K in Q2 2021.
46 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.